Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
Eide CA, Brewer D, Xie T, Schultz AR, Savage SL, Muratcioglu S, Merz N, Press RD, O'Hare T, Jacob T, Vu TQ, Tognon CE, Macey TA, Kuriyan J, Kalodimos CG, Druker BJ.
Eide CA, et al. Among authors: o hare t.
Cancer Cell. 2024 Sep 9;42(9):1486-1488. doi: 10.1016/j.ccell.2024.08.004. Epub 2024 Aug 29.
Cancer Cell. 2024.
PMID: 39214096